Bicara Therapeutics (NASDAQ:BCAX) Earns “Outperform” Rating from Wedbush

Bicara Therapeutics (NASDAQ:BCAX)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a note issued to investors on Tuesday,Benzinga reports. They presently have a $30.00 target price on the stock. Wedbush’s price target would suggest a potential upside of 57.32% from the stock’s current price.

Several other analysts also recently commented on BCAX. Citigroup started coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They set an “outperform” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. Bank of America initiated coverage on Bicara Therapeutics in a research note on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price objective for the company. Citizens Jmp reiterated a “market outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research report on Tuesday. Finally, BTIG Research restated a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

Bicara Therapeutics Price Performance

Shares of BCAX stock traded up $0.03 during trading hours on Tuesday, reaching $19.07. 121,340 shares of the company traded hands, compared to its average volume of 508,677. The firm has a 50-day moving average price of $17.15 and a 200 day moving average price of $16.61. The company has a market cap of $1.04 billion, a P/E ratio of -8.63 and a beta of -0.78. Bicara Therapeutics has a 12-month low of $7.80 and a 12-month high of $20.25.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Monday, March 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.04. Sell-side analysts predict that Bicara Therapeutics will post -2.59 EPS for the current year.

Insider Transactions at Bicara Therapeutics

In other news, CEO Claire Mazumdar sold 36,766 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $19.17, for a total transaction of $704,804.22. Following the sale, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at $6,506,144.64. This represents a 9.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Raben sold 16,300 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $18.52, for a total value of $301,876.00. Following the transaction, the insider owned 55,286 shares of the company’s stock, valued at $1,023,896.72. This represents a 22.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 137,969 shares of company stock valued at $2,586,198 in the last ninety days.

Institutional Investors Weigh In On Bicara Therapeutics

Hedge funds have recently bought and sold shares of the business. Vestal Point Capital LP grew its stake in shares of Bicara Therapeutics by 2.0% in the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock worth $80,529,000 after buying an additional 100,000 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Bicara Therapeutics by 596.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after acquiring an additional 2,771,868 shares during the last quarter. Janus Henderson Group PLC purchased a new position in Bicara Therapeutics in the fourth quarter worth about $44,484,000. Vanguard Group Inc. increased its stake in Bicara Therapeutics by 9.8% during the third quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock worth $34,753,000 after acquiring an additional 195,667 shares during the last quarter. Finally, State Street Corp raised its position in Bicara Therapeutics by 179.5% during the fourth quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after purchasing an additional 1,059,260 shares during the period.

Trending Headlines about Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target from $40 to $42 and maintained a “buy” rating — a bullish analyst action implying ~120% upside from current levels. HC Wainwright Price Target Raise
• Positive Sentiment: Citizens Jmp reaffirmed a “market outperform” rating and set a $31 price target, signaling another analyst vote of confidence (~60% implied upside). Citizens Jmp Rating Reaffirmed
• Positive Sentiment: Company reported Q4 results that beat EPS estimates ($-0.68 vs. -$0.72) and provided a business update: selected 1,500 mg weekly as the Phase 3 dose for ficerafusp alfa, initiated the FORTIFI‑HN01 pivotal trial, and expects an interim analysis mid‑2027 — milestones that materially de‑risk the program. Bicara Q4 Results & Business Update
• Neutral Sentiment: Company commentary and call materials highlighted a strong cash position and program timelines (useful for financing runway but not an immediate price mover). Q4 Earnings Call Highlights
• Neutral Sentiment: Insider activity: CEO Claire Mazumdar sold 8,234 shares (~$154k) in early March, representing ~2.37% of her direct holdings — a modest insider sale that may raise questions for some investors but is small relative to her remaining stake. CEO Share Sale
• Neutral Sentiment: Full earnings call transcript is available for investors who want the management commentary and Q&A details. Earnings Call Transcript

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.